Monoclonal antibodies

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

Monoclonal antibody
#Alentis Therapeutics #Cancer research #FDA #Head and neck cancer #Monoclonal antibodies #Oncology

FDA fast-tracks monoclonal antibody for head and neck cancer

Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody. ALE.C04 is indicated to treat patients with recurrent or metastatic CLDN1-positive head and neck squamous cell carcinoma (HNSCC). Fast Track designation aims to facilitate the development and… Read More

#Editor's Choice #News #Regulatory

Neuroblastoma
#Cancer research #Monoclonal antibodies #Neuroscience #Oncology #Phase II trial #Renaissance Pharma

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More

#Cancer Research #News

Biologics research
#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

Guide: Assessing thermal stability with nanoDSF

A new Guide ‘The biologics researcher’s mini-guide to screening candidates with nanoDSF’ is now available from NanoTemper. Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read More

#News

#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

The biologics researcher’s mini-guide to screening candidates with nanoDSF

Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read this mini-guide to learn: How nanoDSF uses your protein’s intrinsic fluorescence to determine its melting temperature, Tm and onset… Read More

#Intelligence #Resources

Baby on a respirator - RSV
#AstraZeneca #FDA #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

Monoclonal antibody to prevent RSV in babies approved in US

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. The drug is also approved in children up to 24 months of age who… Read More

#News #Regulatory

Monoclonal antibodies
#Astellas Pharma #Cancer research #EMA #Gastrointestinal #Monoclonal antibodies #Oncology

EMA reviews monoclonal antibody for gastric cancer

The European Medicines Agency (EMA) has accepted for regulatory review Astellas Pharma’s marketing authorisation application (MAA) for zolbetuximab, an investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody. The application is for authorisation as a first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose… Read More

#News #Regulatory

#Artificial intelligence (AI) #Cell and gene therapy #Machine learning #Monoclonal antibodies #mRNA #Precision medicine

Right on target: The shift to precision pharmaceuticals

By DDW Editor Reece Armstrong. If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World, it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Artificial intelligence (AI), gene editing, synthetic… Read More

#Exclusive Content

#Animal models #Cancer immunotherapy #Cell therapy #Covid-19 #Humanised Immune System (HIS) #Immunotherapy #Monoclonal antibodies #Mouse models #Oncology #Regulatory

Podcast: Immunotherapy, avelumab and the immunocompromised

This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More

#News

Monoclonal antibody
#Bayer #Evotec #Kidney disease #Monoclonal antibodies #Phase I trial

First patient dosed in trial of antibody for kidney disease

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (mAb) targeting the protein Semaphorin-3A (Sema3A), is being developed as a potential first-to-market… Read More

#News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

This week in drug discovery (26-30 June)  

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More

#News

Peanuts
#Allergy #Antibodies #Antibody #IgGenix #Monoclonal antibodies

Could a monoclonal antibody treat peanut allergy?

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The data shows that nearly all peanut-specific IgE antibodies… Read More

#News

Monoclonal antibodies
#Aulos Bioscience #Cancer research #Immuno-oncology #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

AI-designed monoclonal antibody ‘redirects’ the immune system

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The data indicate that AU-007 is well tolerated in patients with unresectable locally advanced or metastatic cancer and there are early signs of anti-tumour activity. Read More

#Cancer Research #Editor's Choice #News

Monoclonal antibodies
#Monoclonal antibodies #Tiziana Life Sciences #Type 1 diabetes

Tiziana develops intranasal antibody for type 1 diabetes

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. “With the FDA approval of the humanised anti-CD3 mAb TZIELD (teplizumab-mzwv injection) and then its subsequent announced acquisition of Provention Bio by Sanofi for… Read More

#News